Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Dec;4(1):6.
doi: 10.1186/s40345-016-0047-3. Epub 2016 Feb 16.

Behavioral and emotional adverse events of drugs frequently used in the treatment of bipolar disorders: clinical and theoretical implications

Affiliations

Behavioral and emotional adverse events of drugs frequently used in the treatment of bipolar disorders: clinical and theoretical implications

Alejandro Szmulewicz et al. Int J Bipolar Disord. 2016 Dec.

Abstract

Background: Behavioral and emotional adverse events induced by drugs commonly prescribed to patients with bipolar disorders are of paramount importance to clinical practice and research. However, no reviews on the topic have been published so far.

Methods: An extensive search was performed. Reports were reviewed if they described behavioral side effects related to pharmacological treatments for bipolar disorders in healthy subjects or patients with different neuropsychiatric disorders. For this review, lithium, antipsychotics, anticonvulsants and selective serotonin reuptake inhibitors were included.

Results: Apathy or emotional blunting, diminished sexual desire, and inability to cry were reported to be associated with exposure to selective serotonin reuptake inhibitors. Neuroleptic-induced deficit syndrome/emotional detachment and obsessive-compulsive symptomatology and decision-making modifications. A lithium-related amotivational syndrome was also reported in the literature. Furthermore, hypersexuality and obsessive-compulsive symptoms have been noted in subjects treated with lamotrigine.

Limitations: Primary studies on drug-related adverse events are scant so far and most of the data currently available derive from case reports. Moreover, most of the evidence reviewed is based on studies performed on healthy subjects and patients with neuropsychiatric conditions other than bipolar disorders.

Discussion: There is a remarkable dearth of data on behavioral adverse events of pharmacological treatment for bipolar disorders. However, the pieces of evidence available at present, though scant and scattered, suggest that different behavioral adverse events may be related to pharmacological treatment for these disorders. The implications of these findings for research and management of patients with mood disorders are discussed.

Keywords: Apathy; Behavioral adverse events; Bipolar disorder; Cognition; Emotional detachment.

PubMed Disclaimer

Similar articles

Cited by

  • Functional Implications of the CLOCK 3111T/C Single-Nucleotide Polymorphism.
    Ozburn AR, Purohit K, Parekh PK, Kaplan GN, Falcon E, Mukherjee S, Cates HM, McClung CA. Ozburn AR, et al. Front Psychiatry. 2016 Apr 21;7:67. doi: 10.3389/fpsyt.2016.00067. eCollection 2016. Front Psychiatry. 2016. PMID: 27148095 Free PMC article.
  • Online information seeking by patients with bipolar disorder: results from an international multisite survey.
    Conell J, Bauer R, Glenn T, Alda M, Ardau R, Baune BT, Berk M, Bersudsky Y, Bilderbeck A, Bocchetta A, Bossini L, Paredes Castro AM, Cheung EY, Chillotti C, Choppin S, Del Zompo M, Dias R, Dodd S, Duffy A, Etain B, Fagiolini A, Garnham J, Geddes J, Gildebro J, Gonzalez-Pinto A, Goodwin GM, Grof P, Harima H, Hassel S, Henry C, Hidalgo-Mazzei D, Kapur V, Kunigiri G, Lafer B, Lam C, Larsen ER, Lewitzka U, Licht R, Lund AH, Misiak B, Piotrowski P, Monteith S, Munoz R, Nakanotani T, Nielsen RE, O'Donovan C, Okamura Y, Osher Y, Reif A, Ritter P, Rybakowski JK, Sagduyu K, Sawchuk B, Schwartz E, Scippa ÂM, Slaney C, Sulaiman AH, Suominen K, Suwalska A, Tam P, Tatebayashi Y, Tondo L, Vieta E, Vinberg M, Viswanath B, Volkert J, Zetin M, Zorrilla I, Whybrow PC, Bauer M. Conell J, et al. Int J Bipolar Disord. 2016 Dec;4(1):17. doi: 10.1186/s40345-016-0058-0. Epub 2016 Aug 24. Int J Bipolar Disord. 2016. PMID: 27552813 Free PMC article.
  • Lithium side effects and toxicity: prevalence and management strategies.
    Gitlin M. Gitlin M. Int J Bipolar Disord. 2016 Dec;4(1):27. doi: 10.1186/s40345-016-0068-y. Epub 2016 Dec 17. Int J Bipolar Disord. 2016. PMID: 27900734 Free PMC article. Review.
  • From Evidence to Practice: A Comprehensive Analysis of Side Effects in Synthetic Anti-Depressant Therapy.
    Pannu A, Goyal RK. Pannu A, et al. Curr Drug Saf. 2025;20(2):120-147. doi: 10.2174/0115748863301630240417071353. Curr Drug Saf. 2025. PMID: 38676478 Review.

References

    1. Adida M, Maurel M, Kaladjian A, Fakra E, Lazerges P, Da Fonseca D, Belzeaux R, Cermolacce M, Azorin JM. Decision-making and schizophrenia. Encephale. 2011;37:S110–S116. doi: 10.1016/S0013-7006(11)70036-7. - DOI - PubMed
    1. Alkin T, Onur E, Ozerdem A. Co-occurence of blepharospasm, tourettism and obsessive-compulsive symptoms during lamotrigine treatment. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31:1339–1340. doi: 10.1016/j.pnpbp.2007.04.015. - DOI - PubMed
    1. Arnone D, Horder J, Cowen PJ, Harmer CJ. Early effects of mirtazapine on emotional processing. Psychopharmacology (Berl) 2009;203:685–691. doi: 10.1007/s00213-008-1410-6. - DOI - PubMed
    1. Atmaca M, Korkmaz S, Topuz M, Mermi O. Mirtazapine augmentation for selective serotonin reuptake inhibitor-induced sexual dysfunction: a retropective investigation. Psychiatry Investig. 2011;8:55–57. doi: 10.4306/pi.2011.8.1.55. - DOI - PMC - PubMed
    1. Aursnes I, Gjertsen MK. Common adverse events associated with an SSRI: meta-analysis of early paroxetine data. Pharmacoepidemiol Drug Saf. 2008;17(7):707–713. doi: 10.1002/pds.1596. - DOI - PubMed

LinkOut - more resources